This clinical trial is focused on studying daytime urinary incontinence in children. The trial will explore the effects of stopping medication treatment for this condition. The medications involved in the study are solifenacin succinate and mirabegron. Solifenacin succinate, also known by its code name YM-905, is a medication that helps relax the bladder by blocking certain receptors. Mirabegron, also known as YM178, works by activating specific receptors in the bladder to help it hold more urine.

The purpose of the study is to determine if stopping these medications suddenly or gradually affects the likelihood of the incontinence returning. Participants in the study will either stop taking their medication all at once or gradually reduce their dosage over time. The study will monitor the recurrence of incontinence over a period of up to 12 months. Additionally, the study will look for any symptoms that might occur when the medication is stopped.

Participants will be children who have been successfully treated for urinary incontinence with solifenacin and/or mirabegron. The study will track their progress and any changes in their condition after the medication is withdrawn. The goal is to better understand how to manage the discontinuation of these treatments in children who have achieved continence.